Cantor Fitzgerald Weighs in on Verastem FY2025 Earnings

Verastem, Inc. (NASDAQ:VSTM) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Verastem in a research note issued to investors on Thursday, October 30th. Cantor Fitzgerald analyst E. Schmidt forecasts that the biopharmaceutical company will post earnings per share of ($2.60) for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. Cantor Fitzgerald also issued estimates for Verastem’s FY2026 earnings at ($2.06) EPS.

Several other research firms also recently weighed in on VSTM. Royal Bank Of Canada set a $13.00 price target on shares of Verastem and gave the stock an “outperform” rating in a research report on Monday, October 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Verastem in a research report on Wednesday, October 8th. B. Riley upgraded shares of Verastem to a “strong-buy” rating in a research report on Monday, August 25th. Mizuho set a $15.00 price target on shares of Verastem in a report on Wednesday, October 29th. Finally, Wall Street Zen raised shares of Verastem from a “sell” rating to a “hold” rating in a report on Sunday, September 21st. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Verastem has a consensus rating of “Buy” and an average target price of $14.29.

Verastem Stock Down 20.1%

VSTM opened at $7.91 on Monday. The company has a current ratio of 3.46, a quick ratio of 3.44 and a debt-to-equity ratio of 2.06. Verastem has a 1-year low of $3.45 and a 1-year high of $11.24. The company has a market capitalization of $486.78 million, a PE ratio of -2.41 and a beta of 0.89. The firm’s 50 day simple moving average is $9.10 and its two-hundred day simple moving average is $7.36.

Verastem (NASDAQ:VSTM) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.25. The business had revenue of $2.14 million during the quarter, compared to analysts’ expectations of $6.01 million.

Insider Activity

In other news, Director Paul A. Bunn sold 8,333 shares of Verastem stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $9.06, for a total transaction of $75,496.98. Following the sale, the director owned 8,333 shares in the company, valued at $75,496.98. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 9,673 shares of company stock worth $88,813 in the last quarter. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Verastem

Several institutional investors have recently bought and sold shares of VSTM. Armistice Capital LLC purchased a new position in Verastem during the second quarter valued at $8,864,000. Octagon Capital Advisors LP purchased a new position in Verastem during the first quarter valued at $10,372,000. BVF Inc. IL grew its stake in Verastem by 62.1% during the second quarter. BVF Inc. IL now owns 3,404,425 shares of the biopharmaceutical company’s stock valued at $14,128,000 after acquiring an additional 1,303,957 shares in the last quarter. Foresite Capital Management VI LLC purchased a new position in Verastem during the second quarter valued at $5,298,000. Finally, Nantahala Capital Management LLC increased its position in Verastem by 28.5% in the second quarter. Nantahala Capital Management LLC now owns 2,954,735 shares of the biopharmaceutical company’s stock worth $12,262,000 after purchasing an additional 656,194 shares during the last quarter. 88.37% of the stock is owned by hedge funds and other institutional investors.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.